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Background: Elevated C-reactive protein (CRP) concentration is a risk factor for cardiovascular events thatmay add prognostic information. Statin
treatment is associated with significant reductions in CRP concentrations, which appear to be unrelated to the magnitude of LDL-cholesterol
reduction. We investigated the effect of atorvastatin, across its dose range, on high sensitivity (hs)CRP in subjects at high cardiovascular risk.
Methods: ACTFAST was a 12 week, prospective, multicenter, open-label trial in which high-risk subjects were assigned a starting dose of
atorvastatin (10, 20, 40 or 80mg/d) based onLDL-C and status of statin use at screening (1345 statin-free [SF] and 772 previously statin-treated [ST]).
Results: At baseline, ST subjects had significantly lower hsCRP levels than SF subjects (ST group 2.31, 95% CI 2.15, 2.48 mg/L vs. SF
group 3.16, 95% CI 2.98, 3.34 mg/L, pb0.05). In the SF group, atorvastatin 10 to 80 mg significantly (pb0.01) reduced hsCRP levels in a
dose dependent-manner. In ST group, additional hsCRP reductions were observed over the statin used at baseline, which were not dose-
dependent. Atorvastatin significantly decreased hsCRP concentrations in subjects with or without diabetes or the metabolic syndrome.
Conclusions: Atorvastatin treatment at different doses, particularly 80 mg, significantly reduced hsCRP serum concentrations. This reduction
was observed in both SF and ST groups and was independent of the presence of metabolic syndrome and/or diabetes. The beneficial effect of
atorvastatin was evident at 6 weeks, supporting the practice of early introduction of higher doses of atorvastatin in high-risk patients.
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Evidence has accumulated on the role of inflammation in the
pathogenesis of atherosclerosis [1,2]. Atherosclerosis, formerly
considered a disease of lipid accumulation, is characterized by
chronic low-grade vascular inflammation [3,4].
Despite progress in the prevention and treatment of
cardiovascular disease, about half of all myocardial infarc-
tions (MI) and strokes occur in individuals with so-called
“normal” LDL cholesterol (LDL-C) levels [5]. Commonly
used risk algorithms, such as the FraminghamRisk Score, fail
to identify all at-risk individuals, thus, the need for additional
risk factors to improve identification and subsequent care of
subjects at higher risk for coronary heart disease (CHD).
Acute phase reactant C-reactive protein (CRP) is a
circulating pentraxin that plays a crucial role in the innate
immune response and provides a stable plasma biomarker for
low-grade systemic inflammation [6]. Although its role as a
biomarker or amediator of atherosclerosis is still debated, CRP
actively contributes to all stages of atherogenesis, including
endothelial dysfunction, atherosclerotic-plaque formation,
maturation, destabilization and eventual rupture [1,7–9]. A
high concentration of hsCRP has been shown to be a strong
independent risk factor for cardiovascular events [1,2,10–12],
thus, adding prognostic information to traditional risk factors.
In addition to their effects on LDL-C, statins have anti-
inflammatory properties [13,14], as shown by significant
reductions in hsCRP levels that appear to be unrelated to the
magnitude of LDL-C reduction [15–18]. Statins are highly
effective in reducing the risk of cardiovascular events in both
primary and secondary prevention, to a degree that is greater
than predicted on the basis of LDL-C lowering alone. This
may be related to their anti-inflammatory actions. In the
Cholesterol and Recurrent Events (CARE) and Air Force/
Texas Coronary Atherosclerosis Prevention Study
(AFCAPS/TexCAPS), the magnitude of risk reduction
associated with statin therapy was higher among those
with elevated hsCRP levels [19,20]. Furthermore, patients
who had lower hsCRP levels after statin therapy had better
clinical outcomes than those with higher levels [21,22].
The main ACTFAST study investigated the benefits of
selecting the starting dose of atorvastatin based on baseline
LDL-C and current CAD risk status [24]. As a sub-study to
ACTFAST,we investigated the effect of atorvastatin 10, 20, 40
and 80 mg on circulating concentrations of hsCRP in subjects
at high cardiovascular risk, including pre-specified subgroups
of subjects with the metabolic syndrome or diabetes.
2. Methods
2.1. Study design
ACTFASTwas a 12 week, prospective, multicenter, open-label trial that
enrolled subjects (either statin-free [SF], never previously prescribed a statin
or off therapy for at least 2 months; or statin-treated [ST] at baseline) with
CHD, a CHD-equivalent (defined as diabetes, peripheral vascular disease or
cerebrovascular disease) or a 10 year CHD risk N20% [23]. Subjects hadLDL-C N2.6mmol/L and≤5.7mmol/L, triglycerides≤6.8mmol/L, and had
to be willing to follow the NCEP III multifaceted lifestyle approach (or
equivalent). The key exclusion criteria included: current use of atorvastatin or
high dose (N40 mg/d) statin, use of other lipid lowering therapy (eg niacin,
fibrates,…) that could not be discontinued 2 months prior to enrolment, or use
of strong CYP3A4 inhibitors. Subjects were also excluded if they suffered
from significant hepatic or renal impairment, uncontrolled diabetes,
uncontrolled hypertension, uncontrolled primary hypothyroidism, clinically
relevant gastrointestinal disease, elevation of creatine kinase (CK) level,
alcohol or other drug abuse, or any severe disease or surgical procedure
within 3 months of screening. A complete description of inclusion and
exclusion criteria has been published elsewhere [24].
Diabetes was defined according to the 2003 American Diabetes
Association criteria [26] and metabolic syndrome was defined according
to the 2001 National Cholesterol Education Program (NCEP)-III [23].
The institutional review board of all participating centers approved the
ACTFAST study protocol and all participants provided written informed
consent. This study was conducted in compliance with the Declaration of
Helsinki [25].
2.2. Treatment
One week after screening, subjects were assigned to 6 weeks of open-
label treatment with atorvastatin according to their baseline LDL-C level and
prior statin use, followed by an additional 6 weeks of treatment, during
which subjects who had not reached LDL-C targets, were titrated to the next
highest dose of atorvastatin if possible [24]. SF subjects with a baseline
LDL-C of 100–149 mg/dL (2.6–3.8 mmol/L), 150–159 (3.9–4.1 mmol/L),
160–169 (4.2–4.4 mmol/L) and 170–220 mg/dL (4.5–5.7 mmol/L) were
assigned to 10, 20, 40 and 80 mg of atorvastatin, respectively. Based on
comparative potency with other statins, a decision was made that subjects
who were on statin therapy at baseline but whose LDL-C remained above
target would receive double the atorvastatin dose for the same baseline LDL-
C level as compared to their untreated counterparts (up to a maximum of
80 mg), without any washout period [24]. Subjects initially allocated to
atorvastatin 80 mg who did not reach LDL-C targets, were continued at that
dose and a more intense therapeutic lifestyle intervention (NCEP III step 2
diet or equivalent) was recommended [23].
2.3. Laboratory determinations
All assays were performed by a central laboratory (Bio-Inova Life
Sciences International, Paris and Montreal offices). Fasting venous blood
samples were collected at baseline, and after 6 and 12 weeks of atorvastatin
treatment for the measurement of plasma lipids, routine hematology and
chemistry. Direct LDL-C measurement was performed, regardless of
triglyceride levels.
Serum hsCRP was assessed using a high-sensitivity, latex microparticle-
enhanced immunoturbidimetric assay (Tina-Quant; RocheDiagnosticsGmbH)
and measured in batches. The minimum detectable concentration of hsCRP
was 0.03 mg/L. Intra-assay and inter-assay coefficients of variation of hsCRP
assay were 1.34% and 5.70%, respectively. A single measurement was
performed at every time point.
2.4. Statistical analysis
All analyses were performed using the SAS statistical package version
8.2. P-values less than 0.05 were considered statistically significant. Due to
the skewed distribution of serum hsCRP levels, log-transformed values were
used in the analyses, and back transformed for data presentation, yielding
geometric means and 95% confidence intervals (CI). Computed values for
the absolute and percent change in hsCRP concentrations over time for each
study subject were not normally distributed. Thus, after logarithmic
transformation, t-test for paired data was applied to evaluate the significance
of any difference in hsCRP changes over time, both overall and within each
group.
Fig. 1. Percent change from screening in hsCRP plasma levels in statin-free
subjects. ITT, intention-to-treat; PP, per protocol. All pb0.05.
Table 1
Baseline characteristics according to statin group—intent-to-treat study population.
Characteristics Statin-free Statin-treated All subjects
N=1345 N=772 N=2117
Male (N, %) 877 (65.2) 552 (71.5) 1429 (67.5)
Caucasian (N, %) 1254 (93.2) 724 (93.8) 1978 (93.4)
Mean age (y) (mean±SD) 63.0±11.0 63.5±10.1 63.2±10.7
Weight (kg) (mean±SD) 82.3±16.9 80.5±14.7 81.6±16.1
Systolic/diastolic blood pressure 136.7±16.3/ 133.4±16.9/ 135.5±16.6/
(mean±SD) 79.4±10.0 76.9±10.1 78.5±10.1
Smoking (N, %) 308 (22.9) 146 (18.9) 454 (21.4)
Diabetes (N, %) 611 (45.4)⁎ 217 (28.1) 828 (39.1)
CHD (N, %) 675 (50.2)⁎ 625 (81.0) 1300 (61.4)
Metabolic syndrome (N, %) 667 (49.6) 315 (40.8) 982 (46.4)
Hypertension (N, %) 930 (69.1) 509 (65.9) 1439 (68.0)
Current statin used at baseline †Fibrates 11(0.8) Fluvastatin 56 (7.3)
(N, %) Statins 3 (0.2) Lovastatin 42 (5.4)
Resins 1 (0.1) Pravastatin 238 (30.8)
Rosuvastatin 6 (0.8)
Simvastatin 427 (55.3)
Other LLT 10 (1.3)‡
Total cholesterol 5.8 (0.9)⁎ 5.4 (0.8) 5.7 (0.8)
(mmol/L) mean (sd)
LDL-C (mmol/L) mean (sd) 3.9 (0.7)⁎ 3.5 (0.6) 3.7 (0.7)
HDL-C (mmol/L) mean (sd) 1.3 (0.3) 1.3 (0.3) 1.3 (0.3)
Triglycerides (mmol/L) mean (sd) 1.9 (1.0) 1.9 (0.9) 1.9 (0.9)
hsCRP (mg/L) (mean, 95% CI) 3.16 (2.98–3.34)⁎ 2.31 (2.15–2.48) 2.82 (2.69–2.94)
*pb0.05 vs. statin-treated.
†These subjects were not eligible since any LLT at baseline was prohibited in the statin-free group. However, they were retained in intention-to-treat analyses.
‡These 10 subjects were using other LLT (ezetimibe, fibrates, cholestyramine and niacin) at baseline and thus, were not eligible for the study. However, they were
retained in intention-to-treat analyses.
LLT: lipid lowering therapy.
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between SF and ST patients were determined using t-test for unpaired data
after log-transformation of the skewed variables (i.e., hsCRP) or Chi-square
test for categorical data. Correlation coefficients were computed to assess
any association between hsCRP levels and various parameters. Furthermore,
the correlations between the change in hsCRP observed over time and the
change observed for other continuous variables were calculated by using
Spearman's correlation analysis.
Data were analyzed on an intention-to-treat (ITT) and per-protocol basis,
with last observation carried forward (LOCF) being used for missing data.
The ITT population consisted of all subjects assigned a starting dose, who
took at least one dose of study medication, and had at least one subsequent
assessment. The per protocol population consisted of those ITT subjects
who: completed the study as per protocol, were exempt of major protocol
violations, were compliant with study treatment, had a baseline hs-CRP
≤10 mg/L, without acute infectious or inflammatory episode or acute
trauma at the time of blood sampling, and who did not use any anti-
inflammatory/immuno-modulating drugs during the study.
3. Results
The ITT population comprised 2117 subjects (686 on 10 mg (32.4%), 773
on 20 mg (36.5%), 234 on 40 mg (11.1%) and 424 on 80 mg (20.0%)). The
proportions of subjects who completed the study were 94%, 95%, 94% and
90% for the 10, 20, 40 and 80 mg doses, respectively.
Participants were mainly Caucasians (93%) andmale (68%), with a mean
age of 63 years (Table 1). Overall, 21% were current smokers, 39% had
diabetes (97.2% were type 2), and 61% had prior CHD. A lower prevalence
of diabetes and higher prevalence of CHD was observed in the ST group. As
expected from the dose assignment scheme based on LDL-C and statin use at
baseline, the mean baseline TC and LDL-C differed significantly between the
two groups (Table 1). In the ST group, baseline serum hsCRP wassignificantly lower than in the SF group (ST group 2.31, 95%CI 2.15,
2.48 mg/L vs. SF group 3.16, 95% CI 2.98, 3.34 mg/L). Approximately 46%
of the ITT population had baseline hsCRP circulating levels of ≥3 mg/L.
3.1. Effect of atorvastatin on hsCRP concentrations
In the SF group, the mean change from baseline in hsCRP level was
significant (pb0.0001) for all doses (Fig. 1) (10 mg −20.8%, 95% CI
−26.1%, −15.0%; 20 mg −28.0%, 95% CI −36.1%, −18.8%; 40 mg
−23.1%, 95% CI −32.4%, −12.4%; 80 mg −33.6%, 95% CI −40.0%,
Table 3
Change from screening in hsCRP, according to baseline hsCRP category in
statin-treated group—intent-to-treat population.
Dose Baseline hsCRP N Change (%) 95% CI p-value
20 mg b3 mg/L 368 −1.64 −9.23, 6.59 0.6859
≥3 mg/L 221 −39.57 −46.84,−31.32 b0.0001
40 mg b3 mg/L 51 −15.13 −28.41, 0.60 0.0583
≥3 mg/L 23 −26.57 −51.20, 10.50 0.1314
80 mg b3 mg/L 64 −4.28 −25.30, 22.67 0.726
≥3 mg/L 45 −46.09 −56.42, −33.30 b0.0001
All doses b3 mg/L 483 −3.51 −10.15, 3.63 0.3257
≥3 mg/L 289 −39.71 −45.86, −32.86 b0.0001
Fig. 2. Percent change from screening in hsCRP plasma levels in statin-
treated subjects. ITT, intention-to-treat; PP, per protocol. All pb0.05.
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study end (pb0.05). The per protocol analysis confirmed the ITT results.
There were significant reductions in hsCRP compared to baseline at both 6
and 12 weeks of treatment (pb0.01), with further reductions between week 6
and 12 with atorvastatin 20 mg (−13.28%, 95% CI −24.62%, −0.23%,
pb0.05) and 80 mg (−12.14%, 95% CI −20.38%, −3.04%; p=0.01).
In the ST group, the mean percent change from baseline in hsCRP level
was significant (pb0.05) for all doses (20 mg: −18.1%, 95% CI −23.8%,
−12.0%; 40 mg −18.9%, 95% CI −31.4%, −4.0%; 80 mg: −24.5%, 95% CI
−36.7%, −9.9%), but was not dose-dependent (Fig. 2). Similar results were
seen in the per protocol population. Reductions in hsCRP levels were
significant after 6 weeks with atorvastatin 20 and 80 mg doses, and after
12 weeks with all doses. Further decreases in hsCRP between week 6 and 12
were observed with the 20 (−9.0%; 95% CI −15.0%, −2.5%, p=0.007) and
40 mg (−20.7%, 95% CI −34.7%, −3.6%, p=0.02) doses.
3.2. Effect of atorvastatin on hsCRP concentrations according to
hsCRP subgroup
The ITT population was divided into two groups according to baseline
hsCRP of b or ≥3 mg/L. At baseline, 52.9% of 10 mg, 40.9% of 20 mg,
40.2% of 40 mg and 48.8% of 80 mg atorvastatin treated subjects had serum
hsCRP levels ≥3 mg/L.
In SF group, there were significant reductions in hsCRP levels in
subjects with baseline hsCRP levels≥3 mg/mL, but not in those with levels
b3 mg/L, with the 10 to 40 mg doses compared to baseline, and in both
hsCRP subgroups with the 80 mg dose (Table 2). In ST subjects, there were
significant reductions in hsCRP concentrations when baseline was≥3 mg/L
with the 20 and 80 mg doses (Table 3).Table 2
Change from screening in hsCRP, according to baseline hsCRP category in
statin-free group—intent-to-treat population.
Dose Baseline hsCRP N Change (%) 95% CI p-value
10 mg b3 mg/L 323 −0.28 −8.76, 8.99 0.9509
≥3 mg/L 363 −35.41 −41.70, −28.45 b0.0001
20 mg b3 mg/L 89 −9.19 −23.45, 7.72 0.265
≥3 mg/L 95 −42.04 −50.50, −32.13 b0.0001
40 mg b3 mg/L 89 −8.6 −22.25, 7.44 0.272
≥3 mg/L 71 −37.99 −49.42, −23.98 b0.0001
80 mg b3 mg/L 153 −13.93 −25.65, −0.37 0.0446
≥3 mg/L 162 −47.96 −54.39, −40.63 b0.0001
All doses b3 mg/L 654 −6.0 −11.82, 0.21 0.0578
≥3 mg/L 691 −39.76 −43.77, −35.47 b0.00013.3. Effect of atorvastatin on hsCRP concentrations according to
metabolic syndrome status
In the SF group, baseline hsCRP levels were significantly higher in
subjects with documented metabolic syndrome (defined according to the
National Cholesterol Education Program (NCEP)-III [23], n=667) than in
those without (n=674) (3.97, 95% CI 3.67, 4.28 mg/L vs. 2.52, 95% CI
2.33, 2.72 mg/L, pb0.0001). Atorvastatin significantly decreased hsCRP
levels in both subjects with and without metabolic syndrome (Fig. 3a).
In the ST group, subjects with metabolic syndrome (n=315) also had
significantly higher hsCRP levels at baseline (3.0, 95% CI 2.66, 3.37 mg/L)Fig. 3. a: Percent change from screening in hsCRP plasma levels in statin-free
subjects with and without metabolic syndrome. ⁎pb0.05. b: Percent change
from screening in hsCRP plasma levels in statin-treated subjects with and
without metabolic syndrome. ⁎pb0.05.
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as in the SF group, atorvastatin significant reduced hsCRP concentrations,
regardless of presence or absence of metabolic syndrome (Fig. 3b).
3.4. Effect of atorvastatin on hsCRP concentrations according to
diabetes status
In the SF group, baseline hsCRP concentrations were not significantly
different between subjects with diabetes (defined according to the American
Diabetes Association [26], n=611) or without (n=734) (3.29, 95% CI 3.02,
3.59 mg/L vs. 3.05, 95% CI 2.83, 3.28 mg/L, p=0.18). Atorvastatin
significantly decreased hsCRP levels in both subjects with and without
diabetes (Fig. 4a).
Similarly, in the ST group, there were no differences in baseline hsCRP
levels in subjects with (n=217) (2.41, 95% CI 2.10, 2.78 mg/L) or without
diabetes (n=555) (2.27, 95% CI 2.09, 2.46 mg/L, pb0.44). The mean
percent change in hsCRP from baseline was similar in subjects with or
without diabetes (Fig. 4b).
3.5. Correlations with baseline hsCRP levels
In the overall study population, there were low, but significant
(pb0.0001) correlations between baseline hsCRP levels and body weight,
BMI, waist circumference and systolic blood pressure (r=0.19, r=0.28,
r=0.27, r=0.085 respectively), but not with diastolic blood pressure
(p=0.14). At study end, there were no significant correlations betweenFig. 4. a: Percent change from screening in hsCRP plasma levels in statin-free
subjects with and without diabetes. ⁎pb0.05. b: % Percent change from
screening in hsCRP plasma levels in statin-treated subjects with and without
diabetes. ⁎pb0.05.change in hsCRP and body weight (r=−0.023, p=0.28), BMI (r=−0.023,
p=0.28), systolic and diastolic blood pressure (r=0.042 and 0.043,
respectively; p=0.05 for both).
There were small, but statistically significant correlations between
change in hsCRP levels and change in LDL-C (r2=0.0117, pb0.0001) or
total cholesterol concentrations (r2=0.0105, pb0.0001), but none of these
were considered clinically significant.
Atorvastatin was well tolerated. Detailed safety results have been
reported elsewhere [24].4. Discussion
These results demonstrate that treatment with atorvas-
tatin across its dose range, and particularly 80 mg, can
effectively reduce circulating hsCRP serum concentra-
tions. Reductions are observed in both patients who were
statin free and those who were previously treated with a
statin, and are independent of the presence of metabolic
syndrome and diabetes. In ST subjects, additional reduc-
tions in hsCRP were achieved over what was obtained
with the prior statin. The greatest reductions in hsCRP
were observed in subjects with elevated serum hsCRP
levels (≥3 mg/L) at baseline, suggesting that atorvastatin
treatment, especially at the 80 mg dose, may be particu-
larly effective in high risk subjects with chronic low-grade
inflammation.
These results support the concept that the beneficial
effects of statins may be mediated, in part, by anti-
inflammatory effects. HsCRP is an independent risk factor
for atherosclerotic disease [1,2,10–12]. Large randomized
trials have demonstrated that statins significantly reduce
the risk of MI and cardiovascular mortality [27–31], with
a magnitude that is greater than expected based on LDL-C
reduction alone. In addition, meta-analyses suggest that
statins may reduce the risk of stroke to a greater extent
than expected based on cholesterol lowering, and more
than non-statin lipid lowering therapy [32–34]. This
suggests that other factors, such as statin-induced hsCRP
reduction, may have a role to play in reducing cardiovas-
cular events.
In this study, 12 weeks of atorvastatin 80 mg therapy
was associated with 34% and 24% (SF and ST, respec-
tively) reductions in hsCRP levels, which were greater than
those observed in s tudies wi th other s ta t ins
[15,19,21,22,35–39]. Intensive dosing of atorvastatin
helps to attenuate the inflammatory response present in
high-risk patients [18,40]. Because the circulating levels of
inflammatory markers are closely linked to cardiovascular
outcomes, these results may explain the incremental
beneficial effects of atorvastatin over less potent statins.
This is supported by the REVERSAL trial [22], where
intensive therapy with atorvastatin 80 mg slowed the
progression of atherosclerosis more than moderate therapy
with pravastatin40 mg, and after adjustment for the
reduction in lipid levels, the decrease in hsCRP levels
was independently and significantly correlated with the
rate of disease progression [22].
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associated with greater reductions in serum hsCRP levels
than lower doses. Other studies in patients with stable
coronary disease, acute coronary syndromes, or diabetes
have also reported greater reductions in hsCRP with higher
compared to lower doses of statins [16,38–40]. However,
even the lowest dose, atorvastatin 10 mg was associated
with significant reductions in hsCRP levels (SF group 18%
(6 weeks) and 21% (12 weeks)). This is consistent with
studies in patients with acute coronary syndromes [17]. and
hyperlipidemia [15,41]. Considering that dose groups were
of unequal size, the study may have lacked power to find a
difference between individual dosing groups, especially for
the smallest one (e.g. 40 mg). However, when testing across
the whole dose range, a significant dose-response relation-
ship was evident.
In our study, a further significant decrease in hsCRP
levels was observed from 6 to 12 weeks with most doses of
atorvastatin in both SF (20, 80 mg) and ST (20, 40 mg)
groups. In contrast, the SWiss Intervention Trial for lowering
CHolesterol (SWITCH) study showed a significant decrease
in hsCRP levels within the first 4 weeks and no further
decrease at 12 weeks with atorvastatin 10 mg [42]. However,
in the Comparative Atorvastatin Pleiotropic effects (CAP)
study, atorvastatin 80 mg provided additional reductions in
hsCRP concentrations when administered for 6 months (vs.
5 weeks), whereas a plateau was reached after 5 weeks with
the 10 mg dose [18]. This suggests that optimum benefits of
the highest dose (80 mg) may be achieved when treatment is
continued for at least 6 months.
In the overall group, the percentage of patients with
hsCRP ≥3 mg/L was relatively large (about 46%) compared
with other populations [16]. We observed significant
reductions in hsCRP levels at all doses in subjects with
baseline hsCRP levels ≥3 mg/L, but only with the 80 mg
dose in subjects with hsCRP levels b3 mg/L. This suggests
that a significant inhibitory effect of atorvastatin treatment
takes place when high levels of inflammatory markers are
present, but that high dose therapy may decrease inflamma-
tion, regardless of baseline level. This is consistent with
previous results obtained with atorvastatin and other statins
[17,19,42].
In ACTFAST, there were significant additional reductions
of serum hsCRP levels in ST subjects over what was
achieved with the previous statin used at baseline. This was
most evident in subjects with high hsCRP levels (≥3 mg/L),
emphasizing the capacity of higher starting doses of
atorvastatin to reduce the inflammatory state in subjects in
whom LDL-C levels remained above target despite the use of
another statin.
Significant reductions in hsCRP were seen regardless of
the presence of diabetes or metabolic syndrome. Signifi-
cant reduction of hsCRP with pravastatin 40 mg have been
shown to be independent of diabetes, cardiovascular
disease, smoking, aspirin use, hormone replacement
therapy (HRT) use, and lipid levels [19,43]. SF patientswith diabetes experienced reductions in hsCRP of 20% and
37% with atorvastatin 10 and 80 mg, respectively. This was
similar to results of the Diabetes Atorvastatin Lipid
Intervention (DALI) study [16], in which 197 patients
with type 2 diabetes experienced reductions in hsCRP
levels of 14.6% and 46.7% with 10 mg or 80 mg of
atorvastatin.
As shown in other studies [2,19,21,44,45], the statin-
mediated changes in hsCRP in ACTFASTwere independent
of LDL-C or total cholesterol changes. This strongly
suggests that the statin-mediated reduction in hsCRP is
unlikely to be a consequence of the reduction in LDL-C
alone but, rather, is potentially mediated by independent
pathways.
Limitations of our study must be considered: the trial
was not blinded and the dosing groups (especially the
40 mg) were of unequal sizes. The study lacked a control
group, due to ethical considerations. However, it is
unlikely that reduction of hsCRP was due to chance or to
the improvement of disease, since CHD is a chronic
progressive disease and more than 68% of patients
displayed a decrease in hsCRP compared to baseline. A
single hsCRP sample was taken at each time point while
the mean of two samples taken 2 weeks apart would have
been preferable to account for variability in measurements
[46]. Also, this study was not designed nor powered to
investigate the impact of lowering hsCRP concentrations
on the incidence of cardiovascular events, especially
considering its short (12 weeks) follow-up period. Despite
all the evidence behind the use of hsCRP for CHD risk
stratification, studies are ongoing to determine if hsCRP
should be used to guide therapy and what patient
populations are most likely to benefit.
5. Conclusions
Elevated serum hsCRP concentrations provide a useful
marker for cardiovascular risk which, when combined with
traditional risk factors, may help improve global risk
prediction. The reduction in hsCRP levels with statin
therapy may explain the clinical benefits of statins, an
effect that was shown to be independent of LDL-C and TC
lowering in ACTFAST. In addition to effective LDL-C
reduction, selecting a starting dose of atorvastatin tailored
according to the required level of LDL-C reduction and
status of statin use at baseline can help subjects at high risk
achieve significant reduction of hsCRP concentrations. In
ST subjects, such a regimen provided additional 18–24%
reductions in hsCRP over what was attained with the
current statin used at baseline. Our data provide strong
evidence supporting the anti-inflammatory effects of
atorvastatin, particularly the 80 mg dose. This effect is
evident as early as 6 weeks and further supports the
practice of introducing higher doses of atorvastatin early in
the management of patients at high risk for coronary artery
disease.
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